查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085535

勃起功能障礙治療市場：2026-2032年全球市場預測（依治療時間、劑量、病患年齡層、藥物類型、給藥途徑及通路）

Erectile Dysfunction Drugs Market by Treatment Duration, Dosage Strength, Patient Age Group, Drug Type, Mode of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，治療勃起功能障礙的市場規模將達到 46.7 億美元，複合年成長率為 7.82%。

主要市場統計數據
基準年 2025 27.5億美元
預計年份：2026年 29.3億美元
預測年份 2032 46.7億美元
複合年成長率 (%) 7.82%

勃起功能障礙（ED）治療市場由既定的臨床需求所驅動。勃起功能障礙與老齡化、糖尿病、高血壓、心血管疾病、肥胖、吸菸、憂鬱症、攝護腺手術、藥物副作用密切相關。此外，ED有時可能是血管疾病的早期徵兆，這導致泌尿系統、基層醫療、男性健康診所、數位健康平台和零售藥局等管道對實證ED治療的需求持續成長。

磷酸二酯酶5型抑制劑，包括Sildenafil、他達拉非、伐地那非和阿伐那非，仍然是一類重要的藥物，因為在關鍵的臨床指南中，它們被認為是許多男性勃起功能障礙（ED）的一線口服治療藥物，前提是排除禁忌症（特別是硝酸鹽類藥物的使用）。該領域的發展受到多種因素的影響，例如學名藥的普及、遠端醫療處方、藥屋主導的用藥模式、人們對性健康意識的提高，以及導致ED盛行率上升的代謝性和心血管疾病負擔的加重。

ED治療前景的變革性轉變。

這一領域正從專家主導、帶有污名化的領域，轉向更易於獲取、消費者意識更強、數位化驅動的男性健康市場。Sildenafil和他達拉非的非專利擴大了患者的用藥途徑，同時也加劇了價格競爭，尤其是在支付方和消費者都將價格承受能力放在首位的市場中。品牌產品的差異化越來越體現在起效時間、持續時間、耐受性、劑量柔軟性、患者支持以及對受監管供應的信心等方面。

人工智慧對ED治療藥物的累積影響

人工智慧 (AI) 正開始對勃起功能障礙 (ED) 治療市場的各個階段產生影響，從藥物發現和開發到商業化和安全性監測。在研發階段，AI 有助於識別與一氧化氮訊號傳導、內皮功能、荷爾蒙路徑和代謝合併症相關的藥物標靶。它還能輔助化合物篩檢、臨床試驗設計、患者分層和真實世界數據 (REW) 分析，從而提高未來 ED 治療和聯合治療的效率。

關鍵區域洞察：亞太地區、北美地區、歐洲地區、新興市場

亞太地區是勃起功能障礙治療市場最具活力的地區之一，這主要得益於龐大的男性人口、糖尿病和心血管疾病患病率的上升、中產階級醫療保健支出的成長，以及遠距遠端醫療在中國、印度、日本、韓國和澳洲等市場的快速普及。儘管監管差異依然顯著，但診斷率的提高、國內製藥業的增強以及男性健康諮詢接受度的提高，都進一步推動了市場需求。

來自主要組織（東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約）的見解

在東協市場，數位醫療的普及、藥房的現代化以及慢性病患病率的上升，推動了對勃起功能障礙（ED）治療需求的成長，使其日益重要。然而，各國的治療費用和監管力道差異顯著。海灣合作理事會（GCC）是一個高階醫療服務叢集，該地區私人醫療的普及、糖尿病的高發以及消費者尋求私人男性健康解決方案的傾向，都支撐了對品牌藥和高品質學名藥的需求。

對主要ED治療藥物市場關鍵國家的洞察

美國是治療勃起功能障礙藥物的主要市場，這得益於其較高的認知度、廣泛的遠端保健處方箋服務、完善的藥房基礎設施以及Sildenafil和他達拉非專利的廣泛供應。加拿大採用監管完善、以病患可及性為導向的模式，並由醫療專業人員進行嚴格監督。同時，墨西哥市場的發展得益於私人藥房的普及以及對價格合理的學名藥日益成長的需求。巴西是拉丁美洲的主要市場，其龐大的人口基數、不斷擴大的私人醫療保健覆蓋範圍以及日益加重的心血管代謝疾病負擔都為其市場發展提供了支撐。

為行業領導者提供的實用建議

在非專利PDE5抑制劑導致價格預期變化的市場環境下，產業領導者應優先考慮具有臨床可信度的差異化。企業可以透過可靠的品質、快速且隱密的供應、病患教育、禁忌症篩檢支援以及基於實證醫學的起效時間、持續時間、耐受性和給藥便利性等方面的定位來提升競爭力。

調查方法

本執行摘要是基於遠端醫療、附加檔資料庫和藥品供應鏈品質資訊來源的記錄趨勢。

結論

儘管勃起功能障礙（ED）治療市場的核心藥理學已趨於成熟，但它仍在不斷發展，這得益於醫療資源獲取的創新、數位化醫療、學名藥的推廣以及品管的提升。 PDE5抑制劑仍然是ED藥物治療的基礎，但未來產業的發展取決於更安全的處方、更強的患者參與度、打擊仿冒品的措施以及對潛在心血管代謝風險的全面管理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 勃起功能障礙治療市場：依治療時間分類

  • 長期
  • 短期

第8章：勃起功能障礙治療市場：依劑量強度分類

  • 100 mg
  • 25 mg
  • 50 mg

第9章 勃起功能障礙治療市場：依患者年齡層別分類

  • 40-60歲
  • 60歲或以上
  • 40歲以下

第10章 勃起功能障礙治療市場：依藥物類型分類

  • Sildenafil類藥物
  • 他達拉非類藥物
  • 基於伐地那非的藥物
  • 基於阿伐那非的藥物
  • Udenafil

第11章 勃起功能障礙治療市場：依給藥途徑分類

  • 口服藥物
  • 注射藥物

第12章 勃起功能障礙治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 勃起功能障礙治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 勃起功能障礙治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 勃起功能障礙治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Apricus Biosciences, Inc.
  • Aurobindo Pharma Limited
  • Auxilium Pharmaceuticals, Inc.
  • Bayer AG
  • Cipla Limited
  • Dong-A Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Futura Medical plc
  • GlaxoSmithKline plc
  • Lupin Limited
  • Petros Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SK Chemicals Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Vivus Inc.
Product Code: MRR-4348D129FAF4

The Erectile Dysfunction Drugs Market is projected to grow by USD 4.67 billion at a CAGR of 7.82% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.75 billion
Estimated Year [2026] USD 2.93 billion
Forecast Year [2032] USD 4.67 billion
CAGR (%) 7.82%

The erectile dysfunction drugs market is anchored by a well-established clinical need: erectile dysfunction (ED) is strongly associated with age, diabetes, hypertension, cardiovascular disease, obesity, smoking, depression, prostate surgery, and medication-related adverse effects. Because ED can also be an early marker of vascular disease, demand for evidence-based ED treatment continues to expand across urology, primary care, men's health clinics, digital health platforms, and retail pharmacy channels.

Phosphodiesterase type 5 inhibitors, including sildenafil, tadalafil, vardenafil, and avanafil, remain the dominant pharmacological class because major clinical guidelines recognize them as first-line oral therapy for many men with ED when contraindications, especially nitrate use, are excluded. Category development is being shaped by generic availability, telehealth prescribing, pharmacy-led access models, broader sexual wellness awareness, and the rising burden of metabolic and cardiovascular conditions that increase ED prevalence.

Transformative Shifts in the ED Treatment Landscape

The landscape is shifting from a specialist-led, stigma-constrained category to a more accessible, consumer-aware, and digitally enabled men's health market. Generic sildenafil and tadalafil have intensified price competition while expanding patient access, especially in markets where payers and consumers prioritize affordability. Branded differentiation is increasingly tied to onset of action, duration, tolerability, dosage flexibility, patient support, and trust in regulated supply.

Another major shift is channel transformation. Telemedicine, online pharmacy verification, e-prescribing, and discreet home delivery have reduced barriers to consultation and refills. At the same time, regulators and manufacturers are under growing pressure to address counterfeit ED drugs, which are among the most commonly falsified medicines globally due to high demand, privacy concerns, and online purchasing behavior. The most competitive participants are combining clinical credibility, digital convenience, and supply-chain integrity.

Cumulative Impact of Artificial Intelligence on ED Drugs

Artificial intelligence is beginning to influence the erectile dysfunction drugs market across discovery, development, commercialization, and safety monitoring. In research and development, AI can help identify drug targets linked to nitric oxide signaling, endothelial function, hormonal pathways, and metabolic comorbidities. It can also support compound screening, trial design, patient stratification, and real-world evidence analysis, improving the efficiency of future ED therapies and combination approaches.

In commercial operations, AI-enabled platforms can personalize education, improve adherence reminders, support contraindication screening workflows, and route patients to appropriate clinician review. AI also strengthens pharmacovigilance by detecting adverse event signals in structured and unstructured data, and it can help identify suspicious online listings or abnormal distribution patterns linked to counterfeit products. The cumulative impact is not a replacement for clinician judgment but a more precise, safer, and more scalable ED care ecosystem.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Markets

Asia-Pacific is one of the most dynamic regions for erectile dysfunction drugs due to large male populations, rising diabetes and cardiovascular disease prevalence, expanding middle-class healthcare spending, and rapid adoption of telehealth in markets such as China, India, Japan, South Korea, and Australia. Regulatory diversity remains significant, but demand is reinforced by improving diagnosis rates, stronger domestic pharmaceutical manufacturing, and growing acceptance of men's health consultations.

North America remains a mature and innovation-oriented region, supported by high awareness of PDE5 inhibitors, strong digital health infrastructure, and established prescription pathways in the United States and Canada. Latin America is benefiting from greater generic penetration and improving access through private pharmacies, with Brazil and Mexico serving as important demand centers. Europe is characterized by guideline-driven care, broad generic availability, strict pharmacovigilance standards, and increasing pharmacy and digital access models, particularly in large Western European markets.

The Middle East is seeing development through private healthcare investment, medical tourism, and increasing attention to lifestyle-related chronic disease, with GCC countries acting as higher-spending markets. Africa remains more uneven because of affordability constraints, underdiagnosis, and variable regulatory enforcement; however, urbanization, pharmacy expansion, and better chronic disease management are gradually improving access to regulated ED treatment.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as digital healthcare adoption, pharmacy modernization, and rising chronic disease prevalence increase demand for ED treatment, though affordability and regulatory enforcement vary widely by country. The GCC represents a premium access cluster where private healthcare, high diabetes prevalence, and consumer willingness to seek discreet men's health solutions support demand for branded and high-quality generic products.

The European Union offers a regulated and guideline-centered environment in which generics, pharmacovigilance, and cross-border quality standards shape competition. BRICS economies collectively represent substantial patient-access opportunity because of large populations, expanding healthcare access, and a significant burden of diabetes and cardiovascular disease. Within this group, China, India, and Brazil are especially important for scale, while Russia and South Africa present more localized access, pricing, and regulatory dynamics.

G7 countries remain influential because they combine high purchasing power, mature regulatory systems, strong digital health adoption, and advanced clinical practice standards. NATO markets overlap heavily with North America and Europe, making them relevant for organizations prioritizing regulated supply chains, counterfeit prevention, and consistent quality assurance across allied high-income healthcare systems.

Key Country Insights for Major ED Drug Markets

The United States is a leading commercial environment for erectile dysfunction drugs due to high awareness, extensive telehealth prescribing, strong pharmacy infrastructure, and broad availability of generic sildenafil and tadalafil. Canada follows a regulated, access-focused model with strong clinician oversight, while Mexico combines private pharmacy access with growing demand for affordable generics. Brazil is Latin America's key scale market, supported by a large population, expanding private healthcare use, and rising cardiometabolic disease burden.

In Europe, the United Kingdom is notable for pharmacy-led access pathways and strong online consultation models, while Germany and France emphasize regulated prescribing, reimbursement discipline, and high clinical standards. Italy and Spain show steady demand supported by aging populations and established urology care, while Russia remains a sizable but more complex market shaped by pricing, localization, and regulatory conditions.

China and India are central to future patient access because of large patient pools, increasing diagnosis, and expanding domestic pharmaceutical manufacturing. Japan's market reflects high quality expectations, aging demographics, and physician-led care, while Australia combines strong regulation with digital health adoption. South Korea is supported by advanced healthcare infrastructure, strong pharmaceutical capabilities, and growing acceptance of men's health treatment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically credible differentiation in a market where generic PDE5 inhibitors have changed price expectations. Organizations can compete through reliable quality, rapid and discreet access, patient education, contraindication screening support, and evidence-based positioning around onset, duration, tolerability, and dosing convenience.

Manufacturers, pharmacies, and digital health providers should invest in counterfeit prevention, verified online dispensing, serialization, and patient-facing authentication tools. Partnerships with urologists, primary care providers, cardiologists, diabetes clinics, and telehealth platforms can improve diagnosis and safe prescribing. Leaders should also build real-world evidence programs to understand adherence, switching behavior, adverse events, and patient-reported outcomes across age groups and comorbid populations.

Research Methodology

This executive summary is based on secondary research from established clinical, regulatory, and healthcare sources, including urology treatment guidelines, medicine labels, public regulatory databases, peer-reviewed literature on ED risk factors and PDE5 inhibitor use, and documented trends in telehealth, generic medicines, and pharmaceutical supply-chain quality.

The analysis applies a structured market framework covering therapy class, access channel, regional regulation, demand drivers, competitive intensity, and technology impact. Insights were validated through triangulation of clinical evidence, public health trends, regulatory positions, and observable commercial dynamics, with emphasis on verifiable facts rather than speculative market sizing.

Conclusion

The erectile dysfunction drugs market is mature in its core pharmacology but continues to evolve through access innovation, digital care, generic expansion, and stronger quality controls. PDE5 inhibitors remain the foundation of pharmacological ED treatment, while future industry development will depend on safer prescribing, better patient engagement, counterfeit mitigation, and integrated management of underlying cardiometabolic risk.

Organizations that combine evidence-based medicine with convenient, regulated, and patient-centered access will be best positioned to meet demand across established and emerging markets. The strongest opportunities are likely to come from trusted digital pathways, regional access strategies, real-world evidence, and differentiated services around men's health rather than from price competition alone.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Erectile Dysfunction Drugs Market, by Treatment Duration

  • 7.1. Long-Term
  • 7.2. Short-Term

8. Erectile Dysfunction Drugs Market, by Dosage Strength

  • 8.1. 100 Mg
  • 8.2. 25 Mg
  • 8.3. 50 Mg

9. Erectile Dysfunction Drugs Market, by Patient Age Group

  • 9.1. 40-60 Years
  • 9.2. 60+ Years
  • 9.3. Under 40 Years

10. Erectile Dysfunction Drugs Market, by Drug Type

  • 10.1. Sildenafil-based drugs
  • 10.2. Tadalafil-based drugs
  • 10.3. Vardenafil-based drugs
  • 10.4. Avanafil-based drugs
  • 10.5. Udenafil

11. Erectile Dysfunction Drugs Market, by Mode of Administration

  • 11.1. Oral drugs
  • 11.2. Injectable drugs

12. Erectile Dysfunction Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Erectile Dysfunction Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Erectile Dysfunction Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Erectile Dysfunction Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Apricus Biosciences, Inc.
  • 17.2. Aurobindo Pharma Limited
  • 17.3. Auxilium Pharmaceuticals, Inc.
  • 17.4. Bayer AG
  • 17.5. Cipla Limited
  • 17.6. Dong-A Pharmaceutical Co., Ltd.
  • 17.7. Eli Lilly and Company
  • 17.8. Endo International plc
  • 17.9. Futura Medical plc
  • 17.10. GlaxoSmithKline plc
  • 17.11. Lupin Limited
  • 17.12. Petros Pharmaceuticals Inc.
  • 17.13. Pfizer Inc.
  • 17.14. Sanofi S.A.
  • 17.15. SK Chemicals Co., Ltd.
  • 17.16. Sun Pharmaceutical Industries Ltd.
  • 17.17. Teva Pharmaceutical Industries Ltd.
  • 17.18. Viatris Inc.
  • 17.19. Vivus Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LONG-TERM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LONG-TERM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LONG-TERM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SHORT-TERM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHORT-TERM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SHORT-TERM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL 100 MG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL 100 MG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL 100 MG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL 25 MG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL 25 MG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL 25 MG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL 50 MG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL 50 MG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL 50 MG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL 40-60 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL 40-60 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL 40-60 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL 60+ YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL 60+ YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL 60+ YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UNDER 40 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UNDER 40 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UNDER 40 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SILDENAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SILDENAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SILDENAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TADALAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TADALAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TADALAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VARDENAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VARDENAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VARDENAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AVANAFIL-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AVANAFIL-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AVANAFIL-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UDENAFIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UDENAFIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UDENAFIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)